A Mildly Altered Vascular Homeostasis in Early Stage of CKD

REFERENCES

• BuBose TD, Jr. American Society of Nephrology Presidential Address 2006. Chronic kidney disease as a public health threat: New strategy for a growing problem. J Am Soc Nephrol 2007; 18: 1038–1045
   PubMedGoogle Scholar
• K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002; 39: 251–266
   Google Scholar
• Futrakul N, Sila-asna M, Futrakul P. Therapeutic strategy towards renal restoration in chronic kidney disease. Asian Biomedicine 2007; 1: 33–44
   Web of Science ®Google Scholar
• Futrakul N, Butthep P, Futrakul P. Altered vascular homeostasis in chronic kidney disease. Clin Hemorheol Microcirc 2008; 38: 201–207
   PubMed Web of Science ®Google Scholar
• Ruggennenti P, Perna A, Gherardi G, Garini G, Zoccali C, Zoccali C, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359–364
   PubMedGoogle Scholar
• The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RE, et al. Randomized controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440–1443
   PubMed Web of Science ®Google Scholar
• Rossing K, Jacobsen P, Pietraszek L, Parving H-H. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care 2003; 26: 2268–2274
   PubMed Web of Science ®Google Scholar
• Deferrari G, Ravean M, Bersuti V, Leoncini G, Deferrari L. Optimizing therapy in the diabetic patient with renal disease: Antihypertensive treatment. J Am Soc Nephrol 2004; 15: S6–S11
   Google Scholar
• Lewis J. Increasing telmisartan vs amlodipine dose in patients with hypertension, type 2 diabetes and microalbuminuria. Nature Clinical Practice Nephrology 2007; 3: 476–477
   PubMedGoogle Scholar
• Futrakul N, Butthep P, Vongthavarawat V, Futrakul P, Silisalipoch S, Chaivatanarat T, et al. Early detection of endothelial injury and dysfunction in conjunction with correction of hemodynamic maladjustment can effectively restore renal function in type 2 diabetic nephropathy. Clin Hemorheol Microcirc 2006; 34: 373–382
   PubMed Web of Science ®Google Scholar
• Futrakul N, Futrakul P, Siriviriyakul P. Correction of peritubular capillary flow reduction with vasodilators restores function in focal segmental glomerulosclerotic nephrosis. Clin Hemorheol Microcirc 2004; 31: 197–205
   PubMed Web of Science ®Google Scholar
• Futrakul P, Yenrudi S, Futrakul N, Sensirivatana R, Watana D, Laohapaibul K, et al. Tubular function and tubulointerstitial disease. Am J Kidney Dis 1999; 33: 886–891
   PubMed Web of Science ®Google Scholar
• Shimizu A, Kitamura H, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N. Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. Am J Pathol 1997; 151: 1231–1239
   PubMed Web of Science ®Google Scholar
• Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13: 806–816
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Kang DH, Ohashi R, Suga S, Herrera-Acosta J, Rodriguez-Iturbe B, et al. Tubulointerstitial disease: Role of ischemia and microvascular disease. Curr Opin Nephrol Hypertens 2003; 12: 233–241
   PubMed Web of Science ®Google Scholar
• Bohle A, Mackensen-Haen S, Wehrmann M. Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res 1996; 13: 191–195
   Google Scholar
• Futrakul N, Panichakul T, Butthep P, Futrakul P, Jetanalin P, Patumraj S, Siriviriyakul P. Ganoderma lucidum suppresses endothelial cell cytotoxicity and proteinuria in persistent proteinuria focal segmental glomerulosclerosis (FSGS) nephrosis. Clin Hemorheol Microcirc 2004; 31: 267–272
   PubMedGoogle Scholar
• Futrakul N, Tosukhowong P, Patumraj S, Siriviriyakul P, Tipprukmas N, Futrakul P. Treatments of hemodynamic maladjustment and oxidative stress prevent renal disease progression in chronically severe glomerulonephritides. Ren Fail 2003; 25: 839–844
   PubMed Web of Science ®Google Scholar
• Wei Z, Costa K, Al-Medhi AB, Dodir C, Muzykantor V, Fisher AB. Simulated ischaemia in flow-adopted endothelial cells leads to generation of reactive oxygen species and cell signaling. Circ Res 1999; 85: 682–689
   PubMed Web of Science ®Google Scholar
• Malek AM, Izumo J. Molecular aspects of signal transduction of shear stress in the endothelial cell. J Hypertens 1994; 12: 989–1000
   PubMed Web of Science ®Google Scholar
• Frangos JA, Estain SG, McIntiae LV, Ives CL. Flow effects on prostacycline production by cultured human endothelial cells. Science 1984; 227: 1477–1479
   Google Scholar
• Cohen MP, Chen S, Ziyadeh FN, Shea E, Hud EA, Lautenslager GT, Sshearman CW. Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy. Kidney Int 2005; 68: 1554–1561
   PubMedGoogle Scholar
• Futrakul N, Sila-asna M. A default renal regeneration in chronic kidney disease. Clin Hemorheol Microcirc 2007; 36: 265–266
   PubMedGoogle Scholar
• Futrakul N, Panichakul T, Chaisuriya P, Sirisinha S, Patumraj S, Futrakul P. Endothelial cell cytotoxicity and renal hypoperfusion in idiopathic nephrotic syndrome. Nephron 2000; 86: 241–242
   PubMedGoogle Scholar
• Futrakul N, Butthep P, Chunhakarn S, Banyatsappasin W, Futrakul P, Sitprija V. A deficient VEGF enhances endothelial cell loss and impaired renal function. Ren Fail 2006; 28: 449
   PubMed Web of Science ®Google Scholar
• Futrakul N, Butthep P, Futrakul P, Sitprija V. Improvement of renal function in type 2 diabetic nephropathy. Ren Fail 2007; 29: 155–158
   PubMed Web of Science ®Google Scholar
• Futrakul N, Panichakul T, Sirisinha S, Futrakul P, Siriviriyakul P. Renal microvascular abnormality in chronic kidney disease. Ren Fail 2006; 28: 609–612
   PubMedGoogle Scholar
• Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, Koskinen PK, Lemstrom KB. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 2003; 107: 1308–1314
   PubMed Web of Science ®Google Scholar
• Futrakul N, Vongthavarawat V, Sirisalipoch S, Chairatanarat T, Futrakul P, Suwanwalaikorn S. Tubular dysfunction and hemodynamic alteration in normoalbuminuric type 2 diabetes. Clin Hemorheol Microcirc 2005; 32: 59–65
   PubMed Web of Science ®Google Scholar
• Futrakul P, Sitprija V, Yenrudi S, Poshyachinda M, Sensirivatana R, Watana D, Singklwa V, Jungthiraapaanich J, Futrakul N. Glomerular endothelial dysfunction determines disease progression: A hypothesis. Am J Nephrol 1997; 17: 533–540
   PubMed Web of Science ®Google Scholar
• Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63: 1094–1103
   PubMed Web of Science ®Google Scholar